Fosamax and Osteonecrosis of the Jaw: Risk and Causation Evidence

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health to Occupational Exposure: A Legacy of Evidence-Based Risk Assessment

The legacy of general health and science information has long provided a foundation for understanding how therapeutic interventions interact with human physiology. Within this broad context, the dissemination of knowledge about medication safety and adverse effects has been a central pillar, guiding both clinical practice and public awareness. This heritage emphasizes the importance of evidence-based risk assessment, where observational data and longitudinal studies inform the balance between benefit and harm. As such, the transition from a general health perspective to a more focused occupational exposure concern requires a shift in analytical lens—from patient-centered pharmacovigilance to workplace-related hazard identification. In the domain of mass production, particularly in pharmaceutical manufacturing or healthcare settings, workers may encounter active pharmaceutical ingredients such as bisphosphonates during handling, compounding, or disposal. This occupational exposure introduces a distinct variable: sustained, low-level contact that differs from prescribed therapeutic regimens. The pivot here is not to assert causation or mechanism, but to recognize that the same agent associated with a known risk in clinical populations—such as the link between Fosamax and osteonecrosis of the jaw—warrants scrutiny in occupational contexts. Studies examining this risk in general health populations provide a baseline, yet the transition to occupational exposure demands consideration of exposure routes, duration, and cumulative dose in non-patient cohorts. This shift reframes the inquiry from individual treatment outcomes to population-level workplace safety, maintaining the neutral, evidence-informed tone of the legacy heritage while opening a new domain for investigation.

Fosamax and Osteonecrosis of the Jaw: Bridging Clinical Evidence to Occupational Risk

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a known adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation of ONJ involves necrotic bone exposure in the oral cavity, often accompanied by pain, swelling, and infection. Diagnosis is typically based on clinical examination and imaging, with a focus on ruling out other causes such as malignancy or radiation-induced osteonecrosis. The condition is considered a rare but serious adverse effect of antiresorptive therapy. The mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but current research suggests that bisphosphonates suppress bone turnover, which may impair the jawbone's ability to repair microdamage and respond to local stressors such as dental procedures or infection. A multiscale characterization of jawbone tissue has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research highlights the unique structural and cellular properties of the jawbone that may make it particularly vulnerable to the effects of bisphosphonates.

Risk Factors and Evidence from Studies

The risk of ONJ in patients taking Fosamax is influenced by several factors. Known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The timeline between exposure to Fosamax and documented harm varies. The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A cohort study among cancer-free female patients aged 40-89 with, or at risk for, osteoporosis in the United Kingdom Clinical Practice Research Datalink (CPRD Aurum) found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This study underscores that while the absolute risk of ONJ is low, the relative risk increases with longer exposure to bisphosphonates.

Adequacy of Warnings and Causation Considerations

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under "Warnings and Precautions" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This section describes the association, risk factors, and recommendations for management, including discontinuation of treatment for patients requiring invasive dental procedures. The label also notes that the optimal duration of use has not been determined and suggests considering drug discontinuation after 3 to 5 years for low-risk patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the adequacy of these warnings in clinical practice may be questioned, as some patients and healthcare providers may not be fully aware of the risk, particularly given the low absolute incidence. For affected patients, causation-related considerations involve establishing a temporal relationship between Fosamax use and the development of ONJ, excluding other potential causes such as cancer, radiation therapy, or other medications. The timeline of onset, which can range from days to months after starting the drug, and the recurrence of symptoms upon rechallenge, support a causal link. Additionally, the increased risk with longer duration of use and the reduction in risk after discontinuation further strengthen the association. In summary, studies show that Fosamax is associated with an increased risk of osteonecrosis of the jaw, particularly with longer duration of use and in the presence of other risk factors such as invasive dental procedures. The absolute risk remains low, but the relative risk increases significantly with prolonged exposure. The prescribing information includes warnings about this adverse effect, but awareness and preventive measures are crucial for minimizing harm.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is the link between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that inhibits bone resorption. A known adverse effect is osteonecrosis of the jaw (ONJ), a condition of exposed, non-healing bone in the jaw. Studies show that longer duration of Fosamax use increases the relative risk of ONJ, though absolute risk remains low (e.g., 0.05% after 5 years) (https://pubmed.ncbi.nlm.nih.gov/39400702/).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids), poor oral hygiene, pre-existing dental disease, and longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long does it take for Fosamax to cause ONJ?

The time to onset of ONJ symptoms can range from one day to several months after starting Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients improve after stopping the drug, but some may have recurrence if rechallenged.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.